News

UroToday1d
SES AUA 2025: Phase 1 Trial of Mevrometostat (PF-06821497), a Potent and Selective Inhibitor of EZH2, in CRPC
(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Benjamin Garmezy discussing a phase 1 trial of mevrometostat (PF-06821497), a potent and ...
UroToday23h
ASCO 2025: Ipilimumab/nivolumab Versus Standard of Care in Non-Clear Cell Renal Cancer: Results of the SUNNIFORECAST Trial and Potential Role of the CPS Score and Tumor Nephrectomy
ASCO 2025, Renal Cancer, kidney cancer, Non-clear cell renal cell carcinoma (non-ccRCC), Ipilimumab, nivolumab, SUNNIFORECAST Trial, Tumor Nephrectomy, tyrosine kinase inhibitors (TKIs), immune ...
UroToday23h
ASCO GU 2025: STARLITE 2: Phase 2 Study of Nivolumab Plus 177lutetium-Labeled Anti–Carbonic Anhydrase IX (CAIX) Monoclonal Antibody Girentuximab (177Lu-Girentuximab) in ...
ASCO GU 2025 STARLITE 2 trial in progress, nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients with advanced clear ...
UroToday23h
ASCO 2025: Navigating the Crossroads: Evolving Paradigms in Perioperative Management of Muscle-Invasive Bladder Cancer
ASCO 2025, bladder cancer, muscle-invasive bladder cancer (MIBC), trimodal therapy (TMT), SWOG 8710 trial, PURE-01 trial, NIAGARA trial, ABACUS trial, CheckMate 274 trial, ImVigor 010, atezolizumab, ...
UroToday1d
ASCO 2025: Effect of HLA Class I Expression on the Tumor Immune Microenvironment and Prognosis in Prostate Cancer
ASCO 2025 HLA class I expression on the tumor immune microenvironment, prostate cancer, Human leukocyte antigen (HLA) class I, T-cell interactions ...
UroToday1d
ASCO 2025: Clonal Hematopoiesis in Participants with mCRPC Receiving 177Lu-PSMA-617 or Cabazitaxel: An Exploratory Post-Hoc Analysis of a Randomized Phase II Trial (TheraP ...
ASCO 2025 post-hoc analysis of TheraP, clonal hematopoiesis, metastatic castration-resistant prostate cancer (mCRPC), 177Lu-PSMA-617, cabazitaxel, PSMA-targeted radioligand.
UroToday1d
ASCO 2025: CA209-8TY Trial, a Randomized Phase 2 Trial of Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy in mCRPC
ASCO 2025 CA209-8TY trial, phase 2 trial of nivolumab and ipilimumab, stereotactic body radiation therapy, metastatic castration-resistant prostate cancer (mCRPC), androgen receptor pathway inhibitors ...
UroToday1d
ASCO 2025: Association of Circulating Immune and Metabolic Markers with Clinical Outcomes in the ENZAMET Trial (ANZUP 1304)
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...
UroToday1d
ASCO 2025: Assessing Treatment Outcomes of Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer
ASCO 2025, urothelial carcinoma (UC), Metastatic Bladder Cancer, Enfortumab Vedotin (EV), Dose Reduction in Metastatic Bladder Cancer, Nectin-4.
UroToday1d
ASCO 2025: Non-Androgen-Receptor–Driven Prostate Cancer: Updates in Biology, Classification, and Management
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Session State of the Art Lecture: Personalizing treatment for patients with ...
UroToday3d
Procedure for Changing a Suprapubic Catheter (SPC or SPT)
initial insertion of a suprapubic catheter (SPC), suprapubic cystostomy, insertion for bladder outlet obstruction, indwelling urethral catheter (IUC), urology nursing practice, Diane Newman.
UroToday4d
ASCO 2025: Trials-in-Progress – Sasanlimab as Bladder-Sparing Maintenance Treatment After Neoadjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer (MIBC): The ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.